Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest

Alkahest, a company that analyzes blood proteins to develop therapies that address neurological disorders including Alzheimer’s disease, is set to be acquired by partner Grifols in a $146 million deal. Grifols (NASDAQ: GRFS) announced Monday that it is acquiring the shares of privately held Alkahest that it does not already own. Barcelona-based Grifols says the […]

Click to view original post